Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent loss-of-function and gain-of-function studies have revealed that transcription factor Sox9 is required for testis formation by governing Sertoli cell differentiation, and thereafter regulating transcription of Sertoli marker genes. In the present study, we identified a novel isoform of
Vinexin
, which is expressed in somatic cells but not germ cells of sexually indifferent stages of fetal gonads. After the sex is determined, the expression continues in testicular Sertoli cells. Immunohistochemical analyses with a specific antibody to
Vinexin
indicated that
Vinexin
gamma is localized in the cytoplasm. Functional studies with C3H10T1/2 cells showed that
Vinexin
gamma acted as a scaffold protein to activate
MEK
and ERK through interaction with c-Raf and ERK. Ultimately, Sox9 transcription was induced by
Vinexin
gamma. This up-regulation of Sox9 expression disappeared when the cells were treated with a specific
MEK
inhibitor, U0126. To determine the role of
Vinexin
gamma during gonad formation, the gene was disrupted by targeted mutagenesis. The phenotype displayed by the mice indicated that ERK activation was decreased in the
Vinexin
gamma(-/-) XY gonads, and Sox9 expression was down-regulated. Thus,
Vinexin
gamma seems to be implicated in regulation of Sox9 gene expression by modulating MAPK cascade in mouse fetal gonads.
...
PMID:A novel isoform of Vinexin, Vinexin gamma, regulates Sox9 gene expression through activation of MAPK cascade in mouse fetal gonad. 1583 71
CAP/Ponsin belongs to the SoHo family of adaptor molecules that includes ArgBP2 and
Vinexin
. These proteins possess an N-terminal sorbin homology (SoHo) domain and three C-terminal SH3 domains that bind to diverse signaling molecules involved in a variety of cellular processes. Here, we show that CAP binds to the cytoskeletal proteins paxillin and vinculin. CAP localizes to cell-extracellular matrix (ECM) adhesion sites, and this process requires binding to vinculin. Overexpression of CAP induces the aggregation of paxillin, vinculin and actin at cell-ECM adhesion sites. Moreover, CAP inhibits adhesion-dependent processes such as cell spreading and focal adhesion turnover, whereas a CAP mutant that is unable to localize to cell-ECM adhesion sites is incapable of exerting these effects. Finally, depletion of CAP by siRNA-mediated knockdown leads to enhanced cell spreading, migration and the activation of the PAK/
MEK
/ERK pathway in REF52 cells. Taken together, these results indicate that CAP is a cytoskeletal adaptor protein involved in modulating adhesion-mediated signaling events that lead to cell migration.
...
PMID:CAP interacts with cytoskeletal proteins and regulates adhesion-mediated ERK activation and motility. 1708 70
Activation of extracellular signal-regulated kinase (ERK) is known to be regulated by cell adhesion, namely "anchorage dependence". Most studies on the anchorage-dependent regulation have focused on the upstream activating components. We previously reported that the focal adhesion protein
vinexin beta
can induce the anchorage-independent activation of ERK2. We show here that
vinexin beta
-induced anchorage-independent activation of ERK2 involves prevention of the dephosphorylation of ERK2, but not the promotion of
MEK1
or Raf1 activity. Furthermore, knockdown of
vinexin beta
resulted in a faster dephosphorylation of ERK2 in A549 cells. Moreover, the coexpression of MKP3/rVH6, an ERK2 specific phosphatase, suppressed the anchorage-independent activation of ERK2 induced by
vinexin beta
. These results suggest that
vinexin beta
can prevent the dephosphorylation of ERK2 stimulated by cell detachment, leading to the anchorage-independent activation of ERK2. Furthermore, we found that phosphatase activity directed against activated ERK2 was higher in suspended cells than in adherent cells. In addition, orthovanadate efficiently induces anchorage-independent activation of ERK2 without marked activation of
MEK1
in NIH3T3 cells. These observations suggest that the anchorage dependence of ERK1/2 activation is regulated not only by upstream kinases, Raf1 and
MEK
, but also by phosphatases acting against ERK1/2 and that
vinexin beta
can induce anchorage-independent activation of ERK by preventing the inactivation of ERK1/2.
...
PMID:Involvement of phosphatases in the anchorage-dependent regulation of ERK2 activation. 1741 18
Expression of focal adhesion protein
vinexin
is reported to be altered in several cancer tissues; however, the mechanism of expressional change in
vinexin
is not known. Here we report the suppression of
vinexin
expression according to cellular transformation by v-Src. We found that
vinexin
expression was down-regulated both at the mRNA level and at the post-transcriptional level in v-Src-transformed cells. Both mTOR and
MEK
/ERK signals were involved in the suppression. Inhibition of these pathways by pharmacological treatment partially restored both
vinexin
protein and mRNA expression. Moreover, re-expression of
vinexin
in v-Src-transformed cells suppressed cell migration. Taken together, these observations suggest that cellular transformation by v-Src suppressed
vinexin
expression and that down-regulation of
vinexin
may be associated with oncogenic transformation.
...
PMID:v-Src-mediated transformation suppresses the expression of focal adhesion protein vinexin. 1921 6